Genetic basis for prediction of non-responders to dietary plant sterol intervention (GenePredict-PS): a study protocol for a double-blind, placebo-controlled, randomized two-period crossover study
Open Access
- 1 June 2020
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-8
Abstract
Background: Functional food ingredients and natural health products have been demonstrated to reduce disease risk and thereby help to lower health care costs across populations at risk for chronic or degenerative diseases. However, typically a wide range of interindividual variability exists in response across individuals to nutritional and natural health product bioactives, such as plant sterols (PS). This study aims to determine and utilize information on the associations between genosets and the degree of responsiveness to dietary PS intervention, with a long-term objective of developing genetic tests to predict responses to PS. Methods: This clinical trial is designed as a double-blind, placebo controlled, randomized two-period crossover study. Sixty-four eligible participants with the specific a priori-determined single nucleotide polymorphisms (SNPs) associated with a responsiveness to PS will consume PS or a placebo treatment for two 4-week periods. The PS treatment consists of two daily single portions of margarine, each providing 1 g PS during the PS period (2.0 g/day of PS in total). The placebo will be an identical margarine containing no added PS. Low-density lipoprotein cholesterol (LDL-C) responsiveness to the controlled administration of PS will be investigated as the primary outcome, and the associations between interindividual genoset variabilities and response to PS consumption will be determined. Discussion: This research will provide further insight into whether the associations between previously identified SNPs and the response of LDL-C to PS consumption can be used in a predictive manner. It will also provide insight into the complexities of undertaking a nutrigenetic trial with prospective recruitment based on genotype. Trial registration: ClinicalTrials.gov: Identifier: NCT02765516. Registered on 6 May 2016.Keywords
All Related Versions
Funding Information
- Mitacs (12345)
This publication has 17 references indexed in Scilit:
- Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutationsNature Genetics, 2018
- CYP7A1-rs3808607and APOEisoform associate with LDL cholesterol lowering after plant sterol consumption in a randomized clinical trialThe American Journal of Clinical Nutrition, 2015
- Lathosterol-to-cholesterol ratio in serum predicts cholesterol-lowering response to plant sterol consumption in a dual-center, randomized, single-blind placebo-controlled trialThe American Journal of Clinical Nutrition, 2015
- Blood Pressure in Treated Hypertensive Individuals With theMTHFR677TT Genotype Is Responsive to Intervention With RiboflavinHypertension, 2013
- High basal fractional cholesterol synthesis is associated with nonresponse of plasma LDL cholesterol to plant sterol therapyThe American Journal of Clinical Nutrition, 2010
- Continuous Dose-Response Relationship of the LDL-Cholesterol–Lowering Effect of Phytosterol IntakeThe Journal of Nutrition, 2009
- Association between non-responsiveness to plant sterol intervention and polymorphisms in cholesterol metabolism genes: a case-control studyApplied Physiology, Nutrition, and Metabolism, 2008
- Effect of plant sterols and exercise training on cholesterol absorption and synthesis in previously sedentary hypercholesterolemic subjectsTranslational Research, 2007
- Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol LevelsMayo Clinic Proceedings, 2003
- Effectiveness of Altering Serum Cholesterol Levels Without DrugsBaylor University Medical Center Proceedings, 2000